Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
AstraZeneca
Harvard Business School
Colorcon
Medtronic

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,144,872

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,144,872 protect, and when does it expire?

Patent 7,144,872 protects LEXISCAN and is included in one NDA.

This patent has thirty patent family members in twenty-four countries.

Summary for Patent: 7,144,872
Title:N-pyrazole A.sub.2A receptor agonists
Abstract:This specification discloses 2-adenosine N-pyrazole compounds having the following formula: ##STR00001## and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
Inventor(s): Zablocki; Jeff A. (Mountain View, CA), Elzein; Elfatih O. (Freemont, CA), Palle; Venkata (Gurgaon, IN), Belardinelli; Luiz (Palo Alto, CA)
Assignee: CV Therapeutics, Inc. (Palo Alto, CA)
Application Number:11/252,760
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Formulation;

Drugs Protected by US Patent 7,144,872

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes   Start Trial   Start Trial Y Y METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART   Start Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes   Start Trial   Start Trial Y Y METHOD OF MYOCARDIAL IMAGING   Start Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes   Start Trial   Start Trial Y Y METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Baxter
Dow
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.